EPO plus radiotherapy does not improve local-regional control in anemic patients with head and neck cancer
the ONA take:
According to a long-term analysis of a study originally published in 2007, researchers have found that the combination of erythropoietin and radiation therapy did not improve local-regional control for anemic patients with head and neck squamous cell carcinoma who receive radiotherapy or chemoradiotherapy.
The 2007 Radiation Therapy Oncology Group (RTOG) 9903 study was an open-label, randomized, phase III trial that evaluated whether the addition of erythropoietin to radiotherapy would improve disease control in anemia patients with head and neck squamous cell carcinoma.
For this long-term analysis, results showed that the local-regional failure rate was 39.4% for patients who received radiotherapy or chemoradiotherapy without erythropoietin compared with 46.2% for patients who received erythropoietin at 5-year follow-up (HR = 1.40). Researchers found no statistically significant differences in 5-year progression-free survival, overall survival, or 5-year distant metastases rate between the two groups.
The findings suggest that erythropoietin should not be utilized in anemic patients with head and neck squamous cell carcinoma.
Combination erythropoietin and radiation therapy did not improve control for anemic patients with head and neck squamous cell carcinoma.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|